Nintedanib (BIBF-1120) is an orally administered intracellular tyrosine kinase inhibitor (TKI) initially developed as an antitumor agent.
The tablet count favoured Nintedanib. The number of clinic visits and blood test influenced the choice for no treatment. The patients believed that their doctors were more influential than the doctors believed themselves.Emma BriggsGeraldine Burge...
The NDA is up for standard review, and Teva expects the FDA to make its decision in March 2015. Boehringer Ingelheim’s Nintedanib Named Breakthrough Therapy Investigational idiopathic pulmonary fibrosis drug nintedanib was granted Breakthrough Therapy designation, enabling Boehringer Ingelheim to speed...
Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal disease characterized by the accumulation of fibrotic tissue in the lung [1]. While two antifibrotic medications (nintedanib and pirfenidone) [2,3] have been shown to slow disease progression and are currently in use, a signific...
A comparison of an anti-fibrotic efficacy of several PDE4 inhibitors to the two therapies approved by Food and Drug Administration (FDA) for idiopathic pulmonary fibrosis (pirfenidone and nintedanib) showed an equivalent reduction in the lung fibrosis with PDE4 inhibitors to pirfenidone and nintedanib...
Idiopathic pulmonary fibrosisTreatmentBI1015550PamrevlumabPentraxin-2TreprostinilThe approval of nintedanib and pirfenidone has changed the treatment landscape of idiopathic pulmonary fibrosis (IPF); however, both drugs only slow disease progression and are burdened by tolerability issues. We summarize the ...
Food and Drug Administration (FDA) approved two anti-fibrotic drugs, pirfenidone, and nintedanib, for the attenuation of IPF [40]. Nonetheless, there are currently no therapies available to reverse or treat PF in human PCM. In Table 1, the different experimental approaches that have been ...